Open Access Articles- Top Results for Melphalan


File:Melphalan ball-and-stick.png
Systematic (IUPAC) name
Clinical data
Trade names Alkeran
AHFS/ monograph
MedlinePlus a682220
  • (Prescription only)
Oral, intravenous
Pharmacokinetic data
Bioavailability 25% to 89%
Metabolism hydrolysis
Half-life 1.5 ± 0.8 hours
Excretion Renal, significantly metabolised
148-82-3 7pxY
PubChem CID 4053
DrugBank DB01042 7pxY
ChemSpider 405297 7pxY
UNII Q41OR9510P 7pxY
KEGG D00369 7pxY
ChEBI CHEBI:28876 7pxY
Synonyms 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]-propanoic acid
Chemical data
Formula C13H18Cl2N2O2
305.2 g/mol
 14pxY (what is this?)  (verify)

Melphalan (trade name Alkeran, in former USSR also known as Sarcolysin) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents.

An alkylating agent adds an alkyl group (CnH2n+1) to DNA. It attaches the alkyl group to the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring.

Otherwise known as L-Phenylalanine Mustard, or L-PAM, melphalan is a phenylalanine derivative of mechlorethamine.

Mechanism of action

Melphalan chemically alters through alkylation of the DNA nucleotide guanine, and causes linkages between strands of DNA. This chemical alteration inhibits DNA synthesis and RNA synthesis, functions necessary for cells to survive. These changes cause cytotoxicity in both dividing and non-dividing tumor cells.[1]


It is used to treat multiple myeloma,[2] ovarian cancer, AL amyloidosis, and occasionally malignant melanoma.

The agent was first investigated as a possible drug for use in melanoma. It was not found to be effective, but has been found to be effective in the treatment of myeloma.

Melphalan is currently being used to treat ocular retinoblastoma, a pediatric solid tumor. This is accomplished via transarterial catheter based slow pulsed infusion into the ophthalmic artery.[3]


Oral or intravenous; dosing varies by purpose and route of administration as well as patient weight.

Melphalan Prescribing Information: Alkeran[4]

Melphalan Patient Information: MedlinePlus[5]

Melphalan Material Safety Data Sheet (MSDS): Sequoia Research Products[6]

Side effects

Common side effects include:

Less common side effects include:


  1. ^ "Melphalan". National Cancer Institute. Retrieved 4 August 2014. 
  2. ^ Facon T, Mary JY, Hulin C et al. (October 2007). "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial". Lancet 370 (9594): 1209–18. PMID 17920916. doi:10.1016/S0140-6736(07)61537-2. 
  3. ^ Gobin YP, Dunkel IJ, Marr BP et al. (Jun 2011). "Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience". Arch Ophthalmol 129 (6): 732–7. PMID 21320950. doi:10.1001/archophthalmol.2011.5. 
  4. ^
  5. ^
  6. ^